These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 16132165

  • 1. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
    Fleischmann R, Sheldon E, Maldonado-Cocco J, Dutta D, Yu S, Sloan VS.
    Clin Rheumatol; 2006 Feb; 25(1):42-53. PubMed ID: 16132165
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS.
    Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.
    Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreisse A, Thurston H, Litschig S, Sloan VS.
    Curr Med Res Opin; 2005 Apr; 21(4):517-26. PubMed ID: 15899100
    [Abstract] [Full Text] [Related]

  • 4. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
    Wittenberg RH, Schell E, Krehan G, Maeumbaed R, Runge H, Schlüter P, Fashola TO, Thurston HJ, Burger KJ, Trechsel U.
    Arthritis Res Ther; 2006 Apr; 8(2):R35. PubMed ID: 16469112
    [Abstract] [Full Text] [Related]

  • 5. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
    Tannenbaum H, Berenbaum F, Reginster JY, Zacher J, Robinson J, Poor G, Bliddal H, Uebelhart D, Adami S, Navarro F, Lee A, Moore A, Gimona A.
    Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
    Dougados M, Moore A, Yu S, Gitton X.
    Arthritis Res Ther; 2007 Nov; 9(1):R11. PubMed ID: 17266764
    [Abstract] [Full Text] [Related]

  • 7. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
    Fleischmann R, Tannenbaum H, Patel NP, Notter M, Sallstig P, Reginster JY.
    BMC Musculoskelet Disord; 2008 Mar 07; 9():32. PubMed ID: 18328090
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
    Kivitz A, Fairfax M, Sheldon EA, Xiang Q, Jones BA, Gammaitoni AR, Gould EM.
    Clin Ther; 2008 Dec 07; 30(12):2366-77. PubMed ID: 19167595
    [Abstract] [Full Text] [Related]

  • 9. A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis.
    Schnitzer TJ, Dattani ID, Seriolo B, Schneider H, Moore A, Tseng L, Sallstig P, Rebuli R, Maxwell T.
    Clin Rheumatol; 2011 Nov 07; 30(11):1433-46. PubMed ID: 21607551
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O'Brien K, Tershakovec AM.
    Rheumatology (Oxford); 2007 Mar 07; 46(3):496-507. PubMed ID: 16936327
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Schnitzer TJ, Beier J, Geusens P, Hasler P, Patel SK, Senftleber I, Gitton X, Moore A, Sloan VS, Poór G.
    Arthritis Rheum; 2004 Aug 15; 51(4):549-57. PubMed ID: 15334426
    [Abstract] [Full Text] [Related]

  • 12. A prospective, randomized, double-blind, multicenter comparative study on the safety and efficacy of Celecoxib and GCSB-5, dried extracts of six herbs, for the treatment of osteoarthritis of knee joint.
    Park YG, Ha CW, Han CD, Bin SI, Kim HC, Jung YB, Lim HC.
    J Ethnopharmacol; 2013 Oct 07; 149(3):816-24. PubMed ID: 23954277
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety of lumiracoxib 100 mg: an open-label extension of a 13-week randomized controlled trial in patients with primary osteoarthritis of the knee.
    Sheldon EA, Beaulieu A, Paster Z, Yu S, Rebuli R.
    Clin Exp Rheumatol; 2008 Oct 07; 26(4):611-9. PubMed ID: 18799092
    [Abstract] [Full Text] [Related]

  • 14. A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis.
    Lee M, Yoo J, Kim JG, Kyung HS, Bin SI, Kang SB, Choi CH, Moon YW, Kim YM, Han SB, In Y, Choi CH, Kim J, Lee BK, Cho S.
    Clin Orthop Surg; 2017 Dec 07; 9(4):439-457. PubMed ID: 29201297
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand.
    Grifka JK, Zacher J, Brown JP, Seriolo B, Lee A, Moore A, Gimona A.
    Clin Exp Rheumatol; 2004 Dec 07; 22(5):589-96. PubMed ID: 15485012
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of lumiracoxib in osteoarthritis: a review of nine studies.
    Berenbaum F, Grifka J, Brown JP, Zacher J, Moore A, Krammer G, Dutta D, Sloan VS.
    J Int Med Res; 2005 Dec 07; 33(1):21-41. PubMed ID: 15651713
    [Abstract] [Full Text] [Related]

  • 17. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial.
    DeLemos BP, Xiang J, Benson C, Gana TJ, Pascual ML, Rosanna R, Fleming B.
    Am J Ther; 2011 May 07; 18(3):216-26. PubMed ID: 20215961
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial.
    Rother M, Lavins BJ, Kneer W, Lehnhardt K, Seidel EJ, Mazgareanu S.
    Ann Rheum Dis; 2007 Sep 07; 66(9):1178-83. PubMed ID: 17363401
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of PG201 (Layla(®)) and celecoxib in the treatment of symptomatic knee osteoarthritis: a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study.
    Yoo WH, Yoo HG, Park SH, Baek HJ, Lee YJ, Shim SC, Kang SW, Kim HA, Song JS, Suh CH, Choi SJ, Yoon BY, Tae DN, Ko HS, Song YW.
    Rheumatol Int; 2014 Oct 07; 34(10):1369-78. PubMed ID: 24531687
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of celecoxib versus ibuprofen for the treatment of patients with osteoarthritis of the knee: A randomized double-blind, non-inferiority trial.
    Gordo AC, Walker C, Armada B, Zhou D.
    J Int Med Res; 2017 Feb 07; 45(1):59-74. PubMed ID: 28222627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.